Entry Point Capital, LLC Verve Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 37,174 shares of VERV stock, worth $282,894. This represents 0.1% of its overall portfolio holdings.
Number of Shares
37,174Holding current value
$282,894% of portfolio
0.1%Shares
3 transactions
Others Institutions Holding VERV
# of Institutions
182Shares Held
73.3MCall Options Held
85KPut Options Held
215K-
Alphabet Inc. Mountain View, CA12.3MShares$94 Million4.09% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$50.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.96MShares$37.8 Million0.01% of portfolio
-
State Street Corp Boston, MA4.25MShares$32.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$30.5 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $456M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...